

CLAIMS AMENDMENTS

Please amend claim 1 as shown below. All other claims are unchanged.

1 1. (currently amended) A preparation for topically delivering
2 and localizing therapeutic agents, comprising:
3 a vasoconstrictor for retarding vascular dispersion of a
4 therapeutic agent; and

5 a penetration enhancer for facilitating penetration of said
6 vasoconstrictor and said therapeutic agent through a patient's
7 skin; wherein:

8 said therapeutic agent is separate and distinct from said
9 vasoconstrictor itself.

1 2. (original) The preparation of claim 1, said vasoconstrictor
2 comprising *phenylephrine*.

1 3. (original) The preparation of claim 2, wherein:
2 a clinical concentration of said *phenylephrine* is at least
3 approximately 0.125%; and

4 said clinical concentration of said *phenylephrine* is at most
5 approximately 1.0%.

1 4. (original) The preparation of claim 3, wherein said
2 clinical concentration of said *phenylephrine* is approximately
3 0.5%.

1 5. (original) The preparation of claim 1, said vasoconstrictor
2 comprising a vasoconstrictor selected from the vasoconstrictor
3 group consisting of: *ephedrine sulfate, epinephrine, naphazoline,*
4 and *oxymetazoline*.

1 6. (original) The preparation of claim 1, said penetration

2 enhancer comprising *dimethylsulfoxide*.

1 7. (original) The preparation of claim 6, wherein a clinical
2 concentration of said *dimethylsulfoxide* is at most approximately
3 10%.

1 8. (original) The preparation of claim 7, wherein said
2 clinical concentration of said *dimethylsulfoxide* is approximately
3 10%.

1 9. (original) The preparation of claim 1, said penetration
2 enhancer comprising *lecithin*.

1 10. (original) The preparation of claim 9, said penetration
2 enhancer further comprising *ethoxy diglycol*.

1 11. (original) The preparation of claim 9, wherein:

2 a clinical concentration of said *lecithin* is at least
3 approximately 2%; and

4 said clinical concentration of said *lecithin* is at most
5 approximately 50%.

1 12. (original) The preparation of claim 11, wherein:

2 said clinical concentration of said *lecithin* is
3 approximately 10% to 12%.

1 13. (original) The preparation of claim 1:

2 said vasoconstrictor comprising *phenylephrine*; and
3 said penetration enhancer comprising *dimethylsulfoxide*.

1 14. (original) The preparation of claim 13, wherein:

2 a clinical concentration of said *phenylephrine* is at least
3 approximately 0.125%;

4 said clinical concentration of said *phenylephrine* is at most
5 approximately 1.0%; and

6 a clinical concentration of said *dimethylsulfoxide* is at
7 most approximately 10%.

1 15. (original) The preparation of claim 14, wherein:
2 said clinical concentration of said *phenylephrine* is
3 approximately 0.5%; and

4 said clinical concentration of said *dimethylsulfoxide* is
5 approximately 10%.

1 16. (original) The preparation of claim 13, wherein:
2 a ratio of a clinical concentration of said
3 *dimethylsulfoxide* to a clinical concentration of said
4 *phenylephrine* is at most approximately 40 to 1.

1 17. (original) The preparation of claim 1:
2 said vasoconstrictor comprising *phenylephrine*; and
3 said penetration enhancer comprising *lecithin*.

1 18. (original) The preparation of claim 17, said penetration
2 enhancer further comprising *ethoxy diglycol*.

1 19. (original) The preparation of claim 17, wherein:
2 a clinical concentration of said *phenylephrine* is at least
3 approximately 0.125%;
4 said clinical concentration of said *phenylephrine* is at most
5 approximately 1.0%; and
6 a clinical concentration of said *lecithin* is at most
7 approximately 50%.

1 20. (original) The preparation of claim 19, wherein:
2 said clinical concentration of said *phenylephrine* is
3 approximately 0.5%; and
4 said clinical concentration of said *lecithin* is

5 approximately 10% to 12%.

1 21. (original) The preparation of claim 17, wherein:

2 a ratio of a clinical concentration of said *lecithin* to a
3 clinical concentration of said *phenylephrine* is at most
4 approximately 200 to 1.

1 22. (original) The preparation of claim 1, further comprising:
2 said therapeutic agent.

1 23. (original) The preparation of claim 22, particularly for
2 relieving pain, comprising:

3 said therapeutic agent comprising a therapeutic pain-
4 relieving agent;

5 said penetration enhancer for facilitating penetration of
6 said therapeutic pain-relieving agent and said vasoconstrictor
7 through the patient's skin; and

8 said vasoconstrictor for retarding vascular dispersion of
9 said therapeutic agent.

1 24. (original) The preparation of claim 23, said therapeutic
2 pain-relieving agent comprising:

3 a local anesthetic.

1 25. (original) The preparation of claim 24, said local
2 anesthetic comprising *bupivacaine*.

1 26. (original) The preparation of claim 25, wherein:

2 a clinical concentration of said *bupivacaine* is at least
3 approximately 2%; and

4 said clinical concentration of said *bupivacaine* is at most
5 approximately 10%.

1 27. (original) The preparation of claim 26, wherein said

2 clinical concentration of said *bupivacaine* is approximately 5%.

1 28. (original) The preparation of claim 24, said local
2 anesthetic comprising a local anesthetic selected from the local
3 anesthetic group consisting of: *mepivacaine*, *levobupivacaine*,
4 *ropivacaine*, *chloroprocaine*, *procaine*, *lidocaine*, *etidocaine*,
5 *benzocaine*, *tetracaine*, and *prilocaine*.

1 29. (original) The preparation of claim 23, said therapeutic
2 pain-relieving agent comprising:

3 a quick-onset, short-acting non-steroidal anti-inflammatory
4 agent.

1 30. (original) The preparation of claim 29, said quick-onset,
2 short-acting non-steroidal anti-inflammatory agent comprising
3 *ketoprofen*.

1 31. (original) The preparation of claim 30, wherein:

2 a clinical concentration of said *ketoprofen* is at least
3 approximately 5%; and

4 said clinical concentration of said *ketoprofen* is at most
5 approximately 20%.

1 32. (original) The preparation of claim 31, wherein said
2 clinical concentration of said *ketoprofen* is approximately 10%.

1 33. (original) The preparation of claim 29, said quick-onset,
2 short-acting non-steroidal anti-inflammatory agent comprising a
3 quick-onset, short-acting non-steroidal anti-inflammatory agent
4 selected from the quick-onset, short-acting non-steroidal anti-
5 inflammatory agent group consisting of: *diclofenac*, *diflunisal*,
6 *etodolac*, *fenoprofen*, *flurbiprofen*, *ibuprofen*, *indomethacin*, and
7 *tolmetin*.

1 34. (original) The preparation of claim 23, said therapeutic
2 pain-relieving agent comprising:

3 a long-acting non-steroidal anti-inflammatory agent.

1 35. (original) The preparation of claim 34, said long-acting
2 non-steroidal anti-inflammatory agent comprising *piroxicam*.

1 36. (original) The preparation of claim 35, wherein:

2 a clinical concentration of said *piroxicam* is at least
3 approximately 0.5%; and

4 said clinical concentration of said *piroxicam* is at most
5 approximately 4%.

1 37. (original) The preparation of claim 36, wherein said
2 clinical concentration of said *piroxicam* is approximately 1.0%.

1 38. (original) The preparation of claim 34, said long-acting
2 non-steroidal anti-inflammatory agent comprising a long-acting
3 non-steroidal anti-inflammatory agent selected from the long-
4 acting non-steroidal anti-inflammatory agent group consisting of:
5 *celecoxib*, *meloxicam*, *nabumetone*, *naproxen*, *oxaprozin*, *rofecoxib*,
6 *sulindac*, and *valdecoxib*.

1 39. (original) The preparation of claim 23, said therapeutic
2 pain-relieving agent comprising:

3 a local anesthetic; and

4 a quick-onset, short-acting non-steroidal anti-inflammatory
5 agent.

1 40. (original) The preparation of claim 39:

2 said local anesthetic comprising *bupivacaine*; and

3 said quick-onset, short-acting non-steroidal anti-
4 inflammatory agent comprising *ketoprofen*.

1 41. (original) The preparation of claim 23, said therapeutic
2 pain-relieving agent comprising:

3 a local anesthetic; and

4 a long-acting non-steroidal anti-inflammatory agent.

1 42. (original) The preparation of claim 41:

2 said local anesthetic comprising *bupivacaine*; and

3 said long-acting non-steroidal anti-inflammatory agent
4 comprising *piroxicam*.

1 43. (original) The preparation of claim 23, said therapeutic
2 pain-relieving agent comprising:

3 a quick-onset, short-acting non-steroidal anti-inflammatory
4 agent; and

5 a long-acting non-steroidal anti-inflammatory agent.

1 44. (original) The preparation of claim 43:

2 said quick-onset, short-acting non-steroidal anti-
3 inflammatory agent comprising *ketoprofen*; and

4 said long-acting non-steroidal anti-inflammatory agent
5 comprising *piroxicam*.

1 45. (original) The preparation of claim 23, said therapeutic
2 pain-relieving agent comprising:

3 a local anesthetic;

4 a quick-onset, short-acting non-steroidal anti-inflammatory
5 agent; and

6 a long-acting non-steroidal anti-inflammatory agent.

1 46. (original) The preparation of claim 45:

2 said local anesthetic comprising *bupivacaine*;

3 said quick-onset, short-acting non-steroidal anti-

4 inflammatory agent comprising *ketoprofen*; and
5 said long-acting non-steroidal anti-inflammatory agent
6 comprising *piroxicam*.

1 47. (original) The preparation of claim 46, wherein:
2 a clinical concentration of said *bupivacaine* is at least
3 approximately 2%;

4 said clinical concentration of said *bupivacaine* is at most
5 approximately 10%;

6 a clinical concentration of said *ketoprofen* is at least
7 approximately 5%;

8 said clinical concentration of said *ketoprofen* is at most
9 approximately 20%;

10 a clinical concentration of said *piroxicam* is at least
11 approximately 0.5%; and

12 said clinical concentration of said *piroxicam* is at most
13 approximately 4%.

1 48. (original) The preparation of claim 47, wherein:

2 said clinical concentration of said *bupivacaine* is
3 approximately 5%;

4 said clinical concentration of said *ketoprofen* is
5 approximately 10%; and

6 said clinical concentration of said *piroxicam* is
7 approximately 1.0%

1 49. (original) The preparation of claim 22, particularly for
2 treating a viral disease, comprising:

3 said therapeutic agent comprising an antiviral agent;
4 said penetration enhancer for facilitating penetration of

5 said antiviral agent and said vasoconstrictor through the
6 patient's skin; and

7 said vasoconstrictor for retarding vascular dispersion of
8 said antiviral agent.

1 50. (original) The preparation of claim 49, said antiviral
2 agent comprising 2-deoxy-d-glucose.

1 51. (original) The preparation of claim 50, wherein:
2 a clinical concentration of said 2-deoxy-d-glucose is at
3 least approximately 0.1%; and

4 said clinical concentration of said 2-deoxy-d-glucose is at
5 most approximately 0.4%.

1 52. (original) The preparation of claim 51, wherein:
2 said clinical concentration of said 2-deoxy-d-glucose is
3 approximately 0.2%.

1 53. (original) The preparation of claim 49, said antiviral
2 agent comprising an antiviral agent selected from the antiviral
3 agent group consisting of: *podofilox, acyclovir, penciclovir, and*
4 *docosanol.*

1 54. (original) The preparation of claim 23, particularly for
2 relieving pain from a viral disease and treating the viral
3 disease, comprising:

4 said therapeutic agent further comprising an antiviral
5 agent;

6 said penetration enhancer for further facilitating
7 penetration of said antiviral agent through the patient's skin;
8 and

9 said vasoconstrictor for further retarding vascular

10 dispersion of said antiviral agent.

1 55. (original) The preparation of claim 54, said antiviral
2 agent comprising *2-deoxy-d-glucose*.

1 56. (original) The preparation of claim 55, wherein:

2 a clinical concentration of said *2-deoxy-d-glucose* is at
3 least approximately 0.1%; and

4 said clinical concentration of said *2-deoxy-d-glucose* is at
5 most approximately 0.4%.

1 57. (original) The preparation of claim 56, wherein:

2 said clinical concentration of said *2-deoxy-d-glucose* is
3 approximately 0.2%.

1 58. (original) The preparation of claim 54, said antiviral
2 agent comprising an antiviral agent selected from the antiviral
3 agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and
4 *docosanol*.

1 59. (original) The preparation of claim 45:

2 said vasoconstrictor comprising *phenylephrine*;

3 said penetration enhancer comprising a penetration enhancing
4 agent selected from the penetration-enhancing agent group
5 consisting of *dimethylsulfoxide* and *lecithin*;

6 said local anesthetic comprising *bupivacaine*;

7 said quick-onset, short-acting non-steroidal anti-
8 inflammatory agent comprising *ketoprofen*; and

9 said long-acting non-steroidal anti-inflammatory agent
10 comprising *piroxicam*.

1 60. (original) The preparation of claim 59, wherein:

2 a clinical concentration of said *phenylephrine* is at least

3 approximately 0.125%;

4 said clinical concentration of said *phenylephrine* is at most

5 approximately 1.0%;

6 a clinical concentration of said *dimethylsulfoxide* is at

7 most approximately 10%;

8 a clinical concentration of said *lecithin* is at most

9 approximately 50%;

10 a clinical concentration of said *bupivacaine* is at least

11 approximately 2%;

12 said clinical concentration of said *bupivacaine* is at most

13 approximately 10%;

14 a clinical concentration of said *ketoprofen* is at least

15 approximately 5%;

16 said clinical concentration of said *ketoprofen* is at most

17 approximately 20%;

18 a clinical concentration of said *piroxicam* is at least

19 approximately 0.5%; and

20 said clinical concentration of said *piroxicam* is at most

21 approximately 4%.

1 61. (original) The preparation of claim 60, wherein:

2 said clinical concentration of said *phenylephrine* is

3 approximately 0.5%;

4 said clinical concentration of said *bupivacaine* is

5 approximately 5%;

6 said clinical concentration of said *ketoprofen* is

7 approximately 10%; and

8 said clinical concentration of said *piroxicam* is

9 approximately 1.0%.

1 62. (original) The preparation of claim 45, additionally for
2 treating a viral disease, said therapeutic agent further
3 comprising:

4 an antiviral agent.

1 63. (original) The preparation of claim 62:

2 said vasoconstrictor comprising *phenylephrine*;
3 said penetration enhancer comprising a penetration enhancing
4 agent selected from the penetration-enhancing agent group
5 consisting of *dimethylsulfoxide* and *lecithin*;

6 said local anesthetic comprising *bupivacaine*;

7 said quick-onset, short-acting non-steroidal anti-
8 inflammatory agent comprising *ketoprofen*;

9 said long-acting non-steroidal anti-inflammatory agent
10 comprising *piroxicam*; and

11 said antiviral agent comprising *2-deoxy-d-glucose*.

1 64. (original) The preparation of claim 63, wherein:

2 a clinical concentration of said *phenylephrine* is at least
3 approximately 0.125%;

4 said clinical concentration of said *phenylephrine* is at most
5 approximately 1.0%;

6 a clinical concentration of said *dimethylsulfoxide* is at
7 most approximately 10%;

8 a clinical concentration of said *lecithin* is at most
9 approximately 50%;

10 a clinical concentration of said *bupivacaine* is at least
11 approximately 2%;

12 said clinical concentration of said *bupivacaine* is at most
13 approximately 10%;

14 a clinical concentration of said *ketoprofen* is at least
15 approximately 5%;

16 said clinical concentration of said *ketoprofen* is at most
17 approximately 20%;

18 a clinical concentration of said *piroxicam* is at least
19 approximately 0.5%;

20 said clinical concentration of said *piroxicam* is at most
21 approximately 4%;

22 a clinical concentration of said *2-deoxy-d-glucose* is at
23 least approximately 0.1%; and

24 said clinical concentration of said *2-deoxy-d-glucose* is at
25 most approximately 0.4%.

1 65. (original) The preparation of claim 64, wherein:

2 said clinical concentration of said *phenylephrine* is
3 approximately 0.5%;

4 said clinical concentration of said *bupivacaine* is
5 approximately 5%;

6 said clinical concentration of said *ketoprofen* is
7 approximately 10%;

8 said clinical concentration of said *piroxicam* is
9 approximately 1.0%; and

10 said clinical concentration of said *2-deoxy-d-glucose* is
11 approximately 0.2%.

1 66. (original) A method of topically delivering and localizing
2 therapeutic agents, comprising the steps of:

3 using a vasoconstrictor for retarding vascular dispersion of
4 a therapeutic agent; in combination with

5 using a penetration enhancer for facilitating penetration of
6 said vasoconstrictor and said therapeutic agent through a
7 patient's skin.

1 67. (original) The method of claim 66, said step of using said
2 vasoconstrictor further comprising the step of using
3 *phenylephrine*.

1 68. (original) The method of claim 67, further comprising the
2 steps of:

3 using a clinical concentration of said *phenylephrine*, of at
4 least approximately 0.125%; and

5 using said clinical concentration of said *phenylephrine*, of
6 at most approximately 1.0%.

1 69. (original) The method of claim 68, further comprising the
2 step of using said clinical concentration of said *phenylephrine*,
3 of approximately 0.5%.

1 70. (original) The method of claim 66, said step of using said
2 vasoconstrictor further comprising the step of using a
3 vasoconstrictor selected from the vasoconstrictor group
4 consisting of: *ephedrine sulfate*, *epinephrine*, *naphazoline*, and
5 *oxymetazoline*.

1 71. (original) The method of claim 66, said step of using said
2 penetration enhancer further comprising the step of using
3 *dimethylsulfoxide*.

1 72. (original) The method of claim 71, further comprising the
2 step of using a clinical concentration of said *dimethylsulfoxide*,

3 of at most approximately 10%.

1 73. (original) The method of claim 72, further comprising the
2 step of using said clinical concentration of said
3 *dimethylsulfoxide*, of approximately 10%.

1 74. (original) The method of claim 66, said step of using said
2 penetration enhancer further comprising the step of using
3 comprising *lecithin*.

1 75. (original) The method of claim 74, said step of using said
2 penetration enhancer further comprising the step of using *ethoxy*
3 *diglycol*.

1 76. (original) The method of claim 74, further comprising the
2 steps of:

3 using a clinical concentration of said *lecithin*, of at least
4 approximately 2%; and

5 using said clinical concentration of said *lecithin*, of at
6 most approximately 50%.

1 77. (original) The method of claim 76, further comprising the
2 step of:

3 using said clinical concentration of said *lecithin*, of
4 approximately 10% to 12%.

1 78. (original) The method of claim 66:

2 said step of using said vasoconstrictor further comprising
3 the step of using *phenylephrine*; and

4 said step of using said penetration enhancer further
5 comprising the step of using *dimethylsulfoxide*.

1 79. (original) The method of claim 78, further comprising the
2 steps of:

3 using a clinical concentration of said *phenylephrine*, of at
4 least approximately 0.125%;

5 using said clinical concentration of said *phenylephrine*, of
6 at most approximately 1.0%; and

7 using a clinical concentration of said *dimethylsulfoxide*, of
8 at most approximately 10%.

1 80. (original) The method of claim 79, further comprising the
2 steps of:

3 using said clinical concentration of said *phenylephrine*, of
4 approximately 0.5%; and

5 using said clinical concentration of said *dimethylsulfoxide*,
6 of approximately 10%.

1 81. (original) The method of claim 78, further comprising the
2 step of:

3 using a ratio of a clinical concentration of said
4 *dimethylsulfoxide* to a clinical concentration of said
5 *phenylephrine*, of at most approximately 40 to 1.

1 82. (original) The method of claim 66:

2 said step of using said vasoconstrictor further comprising
3 the step of using *phenylephrine*; and

4 said step of using said penetration enhancer further
5 comprising the step of using *lecithin*.

1 83. (original) The method of claim 82, said step of using said
2 penetration enhancer further comprising the step of using *ethoxy*
3 *diglycol*.

1 84. (original) The method of claim 82, further comprising the
2 steps of:

3 using a clinical concentration of said *phenylephrine*, of at
4 least approximately 0.125%;

5 using said clinical concentration of said *phenylephrine*, of
6 at most approximately 1.0%; and

7 using a clinical concentration of said *lecithin*, of at most
8 approximately 50%.

1 85. (original) The method of claim 84, further comprising the
2 steps of:

3 using said clinical concentration of said *phenylephrine*, of
4 approximately 0.5%; and

5 using said clinical concentration of said *lecithin*, of
6 approximately 10% to 12%.

1 86. (original) The method of claim 82, further comprising the
2 step of:

3 using a ratio of a clinical concentration of said *lecithin*
4 to a clinical concentration of said *phenylephrine*, of at most
5 approximately 200 to 1.

1 87. (original) The method of claim 66, further comprising the
2 step of:

3 using said therapeutic agent in combination with using said
4 vasoconstrictor and using said penetration enhancer.

1 88. (original) The method of claim 87, particularly for
2 relieving pain:

3 said step of using said therapeutic agent further comprising
4 the step of using a therapeutic pain-relieving agent; further
5 comprising the steps of:

6 using said penetration enhancer for facilitating penetration

7 of said therapeutic pain-relieving agent and said vasoconstrictor
8 through the patient's skin; and

9 using said vasoconstrictor for retarding vascular dispersion
10 of said therapeutic agent.

1 89. (original) The method of claim 88, said step of using said
2 therapeutic pain-relieving agent further comprising the step of
3 using a local anesthetic.

1 90. (original) The method of claim 89, said step of using said
2 local anesthetic further comprising the step of using
3 *bupivacaine*.

1 91. (original) The method of claim 90, further comprising the
2 steps of:

3 using a clinical concentration of said *bupivacaine*, of at
4 least approximately 2%; and

5 using said clinical concentration of said *bupivacaine*, of at
6 most approximately 10%.

1 92. (original) The method of claim 91, further comprising the
2 step of using said clinical concentration of said *bupivacaine*, of
3 approximately 5%.

1 93. (original) The method of claim 89, said step of using said
2 local anesthetic further comprising the step of using a local
3 anesthetic selected from the local anesthetic group consisting
4 of: *mepivacaine*, *levobupivacaine*, *ropivacaine*, *chloroprocaine*,
5 *procaine*, *lidocaine*, *etidocaine*, *benzocaine*, *tetracaine*, and
6 *prilocaine*.

1 94. (original) The method of claim 88, said step of using said
2 therapeutic pain-relieving agent further comprising the step of

3 using a quick-onset, short-acting non-steroidal anti-inflammatory
4 agent.

1 95. (original) The method of claim 94, said step of using said
2 quick-onset, short-acting non-steroidal anti-inflammatory agent
3 further comprising the step of using *ketoprofen*.

1 96. (original) The method of claim 95, further comprising the
2 step of:

3 using a clinical concentration of said *ketoprofen*, of at
4 least approximately 5%; and

5 said clinical concentration of said *ketoprofen*, of at most
6 approximately 20%.

1 97. (original) The method of claim 96, further comprising the
2 step of using said clinical concentration of said *ketoprofen*, of
3 approximately 10%.

1 98. (original) The method of claim 94, said step of using said
2 quick-onset, short-acting non-steroidal anti-inflammatory agent
3 further comprising the step of using a quick-onset, short-acting
4 non-steroidal anti-inflammatory agent selected from the quick-
5 onset, short-acting non-steroidal anti-inflammatory agent group
6 consisting of: *diclofenac*, *diflunisal*, *etodolac*, *fenoprofen*,
7 *flurbiprofen*, *ibuprofen*, *indomethacin*, and *tolmetin*.

1 99. (original) The method of claim 88, said step of using said
2 therapeutic pain-relieving agent further comprising the step of
3 using a long-acting non-steroidal anti-inflammatory agent.

1 100. (original) The method of claim 99, said step of using said
2 long-acting non-steroidal anti-inflammatory agent further
3 comprising the step of using *piroxicam*.

1 101. (original) The method of claim 100, further comprising the
2 steps of:

3 using a clinical concentration of said *piroxicam*, of at
4 least approximately 0.5%; and

5 using said clinical concentration of said *piroxicam*, of at
6 most approximately 4%.

1 102. (original) The method of claim 101, further comprising the
2 step of using said clinical concentration of said *piroxicam*, of
3 approximately 1.0%.

1 103. (original) The method of claim 99, said step of using said
2 long-acting non-steroidal anti-inflammatory agent further
3 comprising the step of using a long-acting non-steroidal anti-
4 inflammatory agent selected from the long-acting non-steroidal
5 anti-inflammatory agent group consisting of: *celecoxib*,
6 *meloxicam*, *nabumetone*, *naproxen*, *oxaprozin*, *rofecoxib*, *sulindac*,
7 and *valdecoxib*.

1 104. (original) The method of claim 88, said step of using said
2 therapeutic pain-relieving agent further comprising the steps of:

3 using a local anesthetic; and

4 using a quick-onset, short-acting non-steroidal anti-
5 inflammatory agent.

1 105. (original) The method of claim 104:

2 said step of using said local anesthetic further comprising
3 the step of using *bupivacaine*; and

4 said step of using said quick-onset, short-acting non-
5 steroidal anti-inflammatory agent further comprising the step of
6 using *ketoprofen*.

1 106. (original) The method of claim 88, said step of using said
2 therapeutic pain-relieving agent further comprising the steps
3 of::

4 using a local anesthetic; and

5 using a long-acting non-steroidal anti-inflammatory agent.

1 107. (original) The method of claim 106:

2 said step of using said local anesthetic further comprising
3 the step of using *bupivacaine*; and

4 said step of using said long-acting non-steroidal anti-
5 inflammatory agent further comprising the step of using
6 *piroxicam*.

1 108. (original) The method of claim 88, said step of using said
2 therapeutic pain-relieving agent further comprising the steps
3 of::

4 using a quick-onset, short-acting non-steroidal anti-
5 inflammatory agent; and

6 using a long-acting non-steroidal anti-inflammatory agent.

1 109. (original) The method of claim 108:

2 said step of using said quick-onset, short-acting non-
3 steroid anti-inflammatory agent further comprising the step of
4 using *ketoprofen*; and

5 said step of using said long-acting non-steroidal anti-
6 inflammatory agent further comprising the step of using
7 *piroxicam*.

1 110. (original) The method of claim 88, said step of using said
2 therapeutic pain-relieving agent further comprising the steps of:

3 using a local anesthetic;

4 using a quick-onset, short-acting non-steroidal anti-
5 inflammatory agent; and

6 using a long-acting non-steroidal anti-inflammatory agent.

1 111. (original) The method of claim 110:

2 said step of using said local anesthetic further comprising
3 the step of using *bupivacaine*;

4 said step of using said quick-onset, short-acting non-
5 steroidal anti-inflammatory agent further comprising the step of
6 using *ketoprofen*; and

7 said step of using said long-acting non-steroidal anti-
8 inflammatory agent further comprising the step of using
9 *piroxicam*.

1 112. (original) The method of claim 111, further comprising the
2 steps of:

3 using a clinical concentration of said *bupivacaine*, of at
4 least approximately 2%;

5 using said clinical concentration of said *bupivacaine*, of at
6 most approximately 10%;

7 using a clinical concentration of said *ketoprofen*, of at
8 least approximately 5%;

9 using said clinical concentration of said *ketoprofen*, of at
10 most approximately 20%;

11 using a clinical concentration of said *piroxicam*, of at
12 least approximately 0.5%; and

13 using said clinical concentration of said *piroxicam*, of at
14 most approximately 4%.

1 113. (original) The method of claim 112, further comprising the

2 steps of:

3 using said clinical concentration of said *bupivacaine*, of
4 approximately 5%;

5 using said clinical concentration of said *ketoprofen*, of
6 approximately 10%; and

7 using said clinical concentration of said *piroxicam*, of
8 approximately 1.0%.

1 114. (original) The method of claim 87, particularly for
2 treating a viral disease:

3 said step of using said therapeutic agent further comprising
4 the step of using an antiviral agent; further comprising the
5 steps of:

6 using said penetration enhancer for facilitating penetration
7 of said antiviral agent and said vasoconstrictor through the
8 patient's skin; and

9 using said vasoconstrictor for retarding vascular dispersion
10 of said antiviral agent.

1 115. (original) The method of claim 114, said step of using said
2 antiviral agent further comprising the step of using *2-deoxy-d-*
3 *glucose*.

1 116. (original) The method of claim 115, further comprising the
2 steps of:

3 using a clinical concentration of said *2-deoxy-d-glucose*, of
4 at least approximately 0.1%; and

5 using said clinical concentration of said *2-deoxy-d-glucose*,
6 of at most approximately 0.4%.

1 117. (original) The method of claim 116, further comprising the

2 step of:

3 using said clinical concentration of said 2-deoxy-d-glucose,
4 of approximately 0.2%.

1 118. (original) The method of claim 114, said step of using said
2 antiviral agent further comprising the step of using an antiviral
3 agent selected from the antiviral agent group consisting of:
4 *podofilox, acyclovir, penciclovir, and docosanol.*

1 119. (original) The method of claim 88, particularly for
2 relieving pain from a viral disease and treating the viral
3 disease:

4 said step of using said therapeutic agent further comprising
5 the step of using an antiviral agent; further comprising the
6 steps of:

7 using said penetration enhancer for further facilitating
8 penetration of said antiviral agent through the patient's skin;
9 and

10 using said vasoconstrictor for further retarding vascular
11 dispersion of said antiviral agent.

1 120. (original) The method of claim 119, said step of using said
2 antiviral agent further comprising the step of using 2-deoxy-d-
3 glucose.

1 121. (original) The method of claim 120, further comprising the
2 steps of:

3 using a clinical concentration of said 2-deoxy-d-glucose, of
4 at least approximately 0.1%; and

5 using said clinical concentration of said 2-deoxy-d-glucose,
6 of at most approximately 0.4%.

1 122. (original) The method of claim 121, further comprising the
2 step of:

3 using said clinical concentration of said *2-deoxy-d-glucose*,
4 of approximately 0.2%.

1 123. (original) The method of claim 119, said step of using
2 said antiviral agent further comprising the step of using an
3 antiviral agent selected from the antiviral agent group
4 consisting of: *podofilox, acyclovir, penciclovir, and docosanol*.

1 124. (original) The method of claim 110:

2 said step of using said vasoconstrictor further comprising
3 the step of using *phenylephrine*;

4 said step of using said penetration enhancer further
5 comprising the step of using a penetration enhancing agent
6 selected from the penetration-enhancing agent group consisting of
7 *dimethylsulfoxide and lecithin*;

8 said step of using said local anesthetic further comprising
9 the step of using *bupivacaine*;

10 said step of using said quick-onset, short-acting non-
11 steroidal anti-inflammatory agent further comprising the step of
12 using *ketoprofen*; and

13 said step of using said long-acting non-steroidal anti-
14 inflammatory agent further comprising the step of using
15 *piroxicam*.

1 125. (original) The method of claim 124, further comprising the
2 steps of:

3 using a clinical concentration of said *phenylephrine*, of at
4 least approximately 0.125%;

5 using said clinical concentration of said *phenylephrine*, of
6 at most approximately 1.0%;

7 using a clinical concentration of said *dimethylsulfoxide*, of
8 at most approximately 10%;

9 using a clinical concentration of said *lecithin*, of at most
10 approximately 50%;

11 using a clinical concentration of said *bupivacaine*, of at
12 least approximately 2%;

13 using said clinical concentration of said *bupivacaine*, of at
14 most approximately 10%;

15 using a clinical concentration of said *ketoprofen*, of at
16 least approximately 5%;

17 using said clinical concentration of said *ketoprofen*, of at
18 most approximately 20%;

19 using a clinical concentration of said *piroxicam*, of at
20 least approximately 0.5%; and

21 using said clinical concentration of said *piroxicam*, of at
22 most approximately 4%.

1 126. (original) The method of claim 125, further comprising the
2 steps of:

3 using said clinical concentration of said *phenylephrine*, of
4 approximately 0.5%;

5 using said clinical concentration of said *bupivacaine*, of
6 approximately 5%;

7 using said clinical concentration of said *ketoprofen*, of
8 approximately 10%; and

9 using said clinical concentration of said *piroxicam*, of

10 approximately 1.0%.

1 127. (original) The method of claim 110, additionally for
2 treating a viral disease, said step of using said therapeutic
3 agent further comprising the step of using an antiviral agent.

1 128. (original) The method of claim 127:

2 said step of using said vasoconstrictor further comprising
3 the step of using *phenylephrine*;

4 said step of using said penetration enhancer further
5 comprising the step of using a penetration enhancing agent
6 selected from the penetration-enhancing agent group consisting of
7 *dimethylsulfoxide* and *lecithin*;

8 said step of using said local anesthetic further comprising
9 the step of using *bupivacaine*;

10 said step of using said quick-onset, short-acting non-
11 steroidial anti-inflammatory agent further comprising the step of
12 using *ketoprofen*;

13 said step of using said long-acting non-steroidal anti-
14 inflammatory agent further comprising the step of using
15 *piroxicam*; and

16 said step of using said antiviral agent further comprising
17 the step of using *2-deoxy-d-glucose*.

1 129. (original) The method of claim 128, further comprising the
2 steps of:

3 using a clinical concentration of said *phenylephrine*, of at
4 least approximately 0.125%;

5 using said clinical concentration of said *phenylephrine*, of
6 at most approximately 1.0%;

7 using a clinical concentration of said *dimethylsulfoxide*, of
8 at most approximately 10%;

9 using a clinical concentration of said *lecithin*, of at most
10 approximately 50%;

11 using a clinical concentration of said *bupivacaine*, of at
12 least approximately 2%;

13 using said clinical concentration of said *bupivacaine*, of at
14 most approximately 10%;

15 using a clinical concentration of said *ketoprofen*, of at
16 least approximately 5%;

17 using said clinical concentration of said *ketoprofen*, of at
18 most approximately 20%;

19 using a clinical concentration of said *piroxicam*, of at
20 least approximately 0.5%;

21 using said clinical concentration of said *piroxicam*, of at
22 most approximately 4%;

23 using a clinical concentration of said *2-deoxy-d-glucose*, of
24 at least approximately 0.1%; and

25 using said clinical concentration of said *2-deoxy-d-glucose*,
26 of at most approximately 0.4%.

1 130. (original) The method of claim 129, further comprising the
2 steps of:

3 using said clinical concentration of said *phenylephrine*, of
4 approximately 0.5%;

5 using said clinical concentration of said *bupivacaine*, of
6 approximately 5%;

7 using said clinical concentration of said *ketoprofen*, of

8 approximately 10%;

9 using said clinical concentration of said *piroxicam*, of
10 approximately 1.0%; and

11 using said clinical concentration of said *2-deoxy-d-glucose*,
12 of approximately 0.2%.

1 131. (original) The method of claim 66, further comprising the
2 step of:

3 applying said vasoconstrictor and said penetration enhancer
4 to the patient's skin.

1 132. (original) The method of claim 78, further comprising the
2 step of:

3 applying said *phenylephrine* and said *dimethylsulfoxide* to
4 the patient's skin.

1 133. (original) The method of claim 82, further comprising the
2 step of:

3 applying said *phenylephrine* and said *lecithin* to the
4 patient's skin.

1 134. (original) The method of claim 87, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said therapeutic agent to the patient's skin.

1 135. (original) The method of claim 88, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said therapeutic pain-relieving agent to the patient's skin.

1 136. (original) The method of claim 89, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said local anesthetic to the patient's skin.

1 137. (original) The method of claim 90, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said *bupivacaine* to the patient's skin.

1 138. (original) The method of claim 94, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said quick-onset, short-acting non-steroidal anti-
5 inflammatory agent to the patient's skin.

1 139. (original) The method of claim 95, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said *ketoprofen* to the patient's skin.

1 140. (original) The method of claim 99, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said long-acting non-steroidal anti-inflammatory agent to the
5 patient's skin.

1 141. (original) The method of claim 100, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said *piroxicam* to the patient's skin.

1 142. (original) The method of claim 110, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,

4 said local anesthetic, said quick-onset, short-acting non-
5 steroidal anti-inflammatory agent, and said long-acting non-
6 steroidal anti-inflammatory agent to the patient's skin.

1 143. (original) The method of claim 111, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 said *bupivacaine*, said *ketoprofen*, and said *piroxicam* to the
5 patient's skin.

1 144. (original) The method of claim 114, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said antiviral agent to the patient's skin.

1 145. (original) The method of claim 115, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said *2-deoxy-d-glucose* to the patient's skin.

1 146. (original) The method of claim 119, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 therapeutic pain-relieving agent, and said antiviral agent to the
5 patient's skin.

1 147. (original) The method of claim 120, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 therapeutic pain-relieving agent, and said *2-deoxy-d-glucose* to
5 the patient's skin.

1 148. (original) The method of claim 124, further comprising the

2 step of:

3 applying said *phenylephrine*, said penetration enhancing
4 agent selected from the penetration-enhancing agent group
5 consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*,
6 said *ketoprofen*, and said *piroxicam* to the patient's skin.

1 149. (original) The method of claim 127, further comprising the
2 step of:

3 applying said vasoconstrictor, said penetration enhancer,
4 said local anesthetic, said quick-onset, short-acting non-
5 steroidal anti-inflammatory agent, said long-acting non-steroidal
6 anti-inflammatory agent, and said antiviral agent to the
7 patient's skin.

1 150. (original) The method of claim 128, further comprising the
2 step of:

3 applying said *phenylephrine*, said penetration enhancing
4 agent selected from the penetration-enhancing agent group
5 consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*,
6 said *ketoprofen*, said *piroxicam*; and said *2-deoxy-d-glucose* to
7 the patient's skin.